Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study

Fig. 1

Schematic protocol of the REDHART2 study. Schematic protocol of the REDHART2 study to investigate the potential effects of anakinra in a randomized double-blind placebo-controlled clinical trial. Patients will be followed for 24 weeks. Lab tests, questionnaires, bio-electrical impedance analysis, echocardiogram and cardiopulmonary exercise testing will be done at baseline, 6, 12, and 24 weeks. Visit 1.5 (after 2 weeks) is considered a safety follow-up assessment

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us